| Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (NCT05106192) | Case Comprehensive Cancer Center | 2022-04-01 |
| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells (NCT04911478) | Adicet Therapeutics | 2022-02-14 |
| Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study (NCT04982471) | Celgene | 2021-11-03 |
| A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan (NCT05228158) | Eisai Co., Ltd. | 2021-08-16 |
| Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (NCT05784415) | AIDS Malignancy Consortium | 2021-05-22 |
| A Phase 1 Study of ADI-001 in B Cell Malignancies (NCT04735471) | Adicet Therapeutics | 2021-03-04 |
| A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (NCT03934567) | Xynomic Pharmaceuticals, Inc. | 2020-04-22 |
| A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea (NCT04036448) | Celgene | 2019-11-28 |
| Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma (NCT03921879) | Oncotartis, Inc. | 2019-07-29 |
| A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma (NCT04370405) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2019-04-29 |
| Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma (NCT03682796) | Triphase Research and Development III Corp. | 2018-10-15 |
| A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma (NCT03357627) | Calithera Biosciences, Inc | 2018-02-16 |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (NCT03310619) | Celgene | 2017-12-20 |
| A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma (NCT02809053) | Archigen Biotech Limited | 2017-01-18 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (NCT02743546) | Janssen Research & Development, LLC | 2016-07-20 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) (NCT02669017) | ADC Therapeutics S.A. | 2016-03-01 |
| A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma (NCT02631577) | Hoffmann-La Roche | 2015-12-31 |
| An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma (NCT02413489) | Janssen Research & Development, LLC | 2015-09-02 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma (NCT02343536) | Celgene | 2015-04-29 |
| A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) (NCT02278796) | Insel Gruppe AG, University Hospital Bern | 2015-04-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (NCT02208037) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-01 |
| To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan (NCT02162771) | Celltrion | 2014-07-14 |
| Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (NCT02390869) | Fondazione Italiana Linfomi - ETS | 2014-05-01 |
| A Phase II Study of Doxycycline in Relapsed NHL (NCT02086591) | University of Rochester | 2014-03-01 |
| Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma (NCT01950273) | Boehringer Ingelheim | 2013-09-27 |
| Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon (NCT03087929) | Sunnybrook Health Sciences Centre | 2013-09-20 |
| Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim (NCT03057418) | Biointegrator LLC | 2013-06-01 |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma (NCT01786135) | Seagen Inc. | 2013-02-01 |
| An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma (NCT01609036) | Hoffmann-La Roche | 2012-10-01 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab (NCT01307267) | Pfizer | 2011-06-21 |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas (NCT01263418) | UNC Lineberger Comprehensive Cancer Center | 2011-06-01 |
| Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma (NCT01208896) | University Hospital, Bordeaux | 2011-02-03 |
| Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (NCT01234766) | Dartmouth-Hitchcock Medical Center | 2010-10-01 |
| Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (NCT01077518) | Novartis Pharmaceuticals | 2010-08-26 |
| Autologous Vaccine for Follicular Lymphoma (NCT01022255) | Icon Genetics GmbH | 2010-01-01 |
| A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma (NCT00930514) | Hoffmann-La Roche | 2009-09-01 |
| Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) (NCT00864227) | Medical College of Wisconsin | 2008-12-01 |
| Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) (NCT00849147) | Medical College of Wisconsin | 2008-10-01 |
| A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma (NCT02472756) | Hoffmann-La Roche | 2008-09-19 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL (NCT00546793) | Gilead Sciences | 2008-01-01 |
| Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) (NCT00562965) | Pfizer | 2007-11-01 |
| Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma (NCT00915096) | Lymphoma Study Association | 2007-09-18 |
| A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin (NCT01164696) | Bayer | 2007-08-01 |
| Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients (NCT00494780) | GlaxoSmithKline | 2007-06-01 |
| A Study of Enzastaurin in Participants With Follicular Lymphoma (NCT00475644) | Eli Lilly and Company | 2007-05-01 |
| Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) (NCT00427856) | Gemin X | 2007-03-01 |
| Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma (NCT00510887) | Duke University | 2007-01-01 |
| Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) (NCT00384111) | Spectrum Pharmaceuticals, Inc | 2006-10-01 |
| Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma (NCT00308087) | Genzyme, a Sanofi Company | 2006-05-01 |
| An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma (NCT01902862) | Janssen-Cilag G.m.b.H | 2006-02-01 |
| A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen (NCT00319332) | GlaxoSmithKline | 2005-09-01 |
| A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NCT00193492) | SCRI Development Innovations, LLC | 2005-09-01 |
| A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma (NCT02569996) | Hoffmann-La Roche | 2005-07-01 |
| Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma (NCT00060671) | CTI BioPharma | 2005-01-01 |
| Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma (NCT00092274) | GlaxoSmithKline | 2004-09-01 |
| A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma (NCT00315731) | GlaxoSmithKline | 2003-03-31 |
| Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) (NCT01250223) | Associazione Angela Serra per la ricerca sul cancro | 2003-02-01 |
| A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma (NCT00081809) | Agenus Inc. | 2000-03-01 |
| FCM Versus R-FCM Followed by R-Maintenance or Observation Only (NCT00317096) | Ludwig-Maximilians - University of Munich | 1998-11-01 |